**FORM 5A**

**ANNUAL LISTING SUMMARY**

**Introduction**

The requirement to file this Form 5A does not apply to NV Issuers. NV Issuers must file a Form 51-102F2 Annual Information Form.

This Annual Listing Summary must be posted on or before the day on which the Issuer’s annual financial statements are to be filed under the Securities Act. This statement is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies.

**General Instructions**

1. Prepare this Annual Listing Summary using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
2. The term “Issuer” includes the Listed Issuer and any of its subsidiaries.
3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

|  |
| --- |
| **Listed Issuer Name: Nanosphere Health Sciences Inc.****Website: https://nanospherehealth.com****Listing Statement Date: April 29, 2024****Description(s) of listed securities(symbol/type): NSHS (common)** |
| **Brief Description of the Issuer's Business: The Issuer continues in its efforts to commercialize and monetize the NanoSphere Delivery System through the pursuit of collaborative research projects and third-party license arrangements to manufacture and sell products based on its proprietary technology, including renewed discussions with Delta-9.** |
| **Description of additional (unlisted) securities outstanding: N/A** |
| **Jurisdiction of Incorporation: British Columbia** |
| **Fiscal Year End: December 31, 2023** |
| **Date of Last Shareholders' Meeting and Date of Next Shareholders' Meeting (if scheduled): December 14, 2023** |
| **Financial Information as at: December 31, 2023** |
| **Cash****Current Assets****Non-current Assets****Current Liabilities****Non-current Liabilities****Shareholders’ equity (deficiency)****Revenue****Net Income (Loss)****Net Cash Flow from Operations** | **Current****$9,316****$17,972****$nil****$1,574,433****$nil****($1,556,461)****$nil****($208,680)****($53,699)** | **Previous****$55,011****$60,049****$nil****$1,371,924****$nil****($1,311,875)****$nil****($246,272)****($67,660)** |

**SUPPLEMENTARY INFORMATION**

The supplementary information set out below must be provided when not included in the Schedules. If the required details are included in Schedule A or B, provide specific reference to the page or note.

1. **Related party transactions**

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

*See the Issuer’s Financial Statements for the year ended December 31, 2023 attached as Schedule A and Management Discussion & Analysis attached as Schedule B.*

1. **Summary of securities issued and options granted during the period.**

*See the Issuer’s Financial Statements for the year ended December 31, 2023 attached as Schedule A and Management Discussion & Analysis attached as Schedule B.*

1. **Summary of securities as at the end of the reporting period.**

*See the Issuer’s Financial Statements for the year ended December 31, 2023 attached as Schedule A and Management Discussion & Analysis attached as Schedule B.*

1. **List the names of the directors and officers and include the position(s) held and the date of appointment, as at the date this report is signed and filed.**

|  |  |
| --- | --- |
| ***Name*** | ***Position*** |
| *Michael Iverson, appointed November 17, 2017* | *Chair, Interim CFO* |
| *Toby Lim, appointed November 17, 2017* | *Director, Interim CEO* |
| *Richard Kaufman, appointed December 14, 2023* | *Director* |

**5. Financial Resources**

*See the Issuer’s Financial Statements for the year ended December 31, 2023 attached as Schedule A and Management Discussion & Analysis attached as Schedule B.*

**6. Status of Operations**

*See the Issuer’s Financial Statements for the year ended December 31, 2023 attached as Schedule A and Management Discussion & Analysis attached as Schedule B.*

**7. Business Activity**

*See the Issuer’s Financial Statements for the year ended December 31, 2023 attached as Schedule A and Management Discussion & Analysis attached as Schedule B.*

**SCHEDULE A**: **AUDITED ANNUAL** **FINANCIAL STATEMENTS**

**SCHEDULE B: MANAGEMENT DISCUSSION AND ANALYSIS**

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Annual Listing Summary.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated April 29, 2024

 Michael Iverson
Name of Director or Senior Officer

 */s/ “Michael Iverson”*
Signature

Chair, Interim Chief Financial Officer
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***Name of IssuerNanoSphere Health Sciences Inc. | For Year EndedDecember 31, 2023 | Date of ReportYY/MM/D24/04/29 |
| Issuer Address488 – 1090 West Georgia Street |
| City/Province/Postal CodeVancouver, BC, V6E 3V7 | Issuer Fax No.N/A | Issuer Telephone No.604-351-3351 |
| Contact NameMichael Iverson | Contact PositionChair & Interim CFO | Contact Telephone No.604-351-3351 |
| Contact Email Addressmike@miversion.ca | Web Site Addresshttps://nanospherehealth.com |